Krishan Jethwa, GI Radiation Oncologist at Mayo Clinic, shared a post on X:
“LAPIS Trial.
Locally advanced PDAC.
Randomized
SoC Systemic therapy (FOLFIRINOX or GnP)
+/-
Pamrevlumab (PAM)
Unfortunately, no improvement in OS, EFS or objective response with addition of PAM.”
More posts featuring Krishan Jethwa.
